Black Diamond Therapeutics
BDTX
65 hedge funds and large institutions have $556M invested in Black Diamond Therapeutics in 2020 Q1 according to their latest regulatory filings, with 65 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
62.09% more ownership
Funds ownership: 0% → 62.09% (+62%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$105M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$78.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$61.3M |
| 4 |
AG
Artal Group
Luxembourg
|
+$51.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.3M |
Top Sellers
BDTX Hedge Fund Activity: Q1 2020 in Review
65 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2020, worth a combined $556M.
Buyers outnumbered sellers: 65 funds opened new BDTX positions and 0 closed out — a net gain of 65 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $105M.
- 65 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $556M of Black Diamond Therapeutics stock for Q1 2020.
- 65 funds opened new Black Diamond Therapeutics positions in Q1 2020 and 0 closed out, a net change of +65 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2020 was NEA Management Company, an estimated $105M added.
Based on aggregated 13F filings for Q1 2020.